In contrast, TRAs involved in RXRA, KDM5B, STAT1, GATA1, HDAC1, RCOR1, PHF8, and CHD2 appeared to be selectively mutated in transformed AML cells during Aza treatment. The gene discussed is CHD2; the disease is acute myeloid leukemia.